Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$50,000,000 share offering. This is adding approximately 1/6 the structure. Decent dilution still not enough to keep the doors open for a year.
very nice push coming....rare disease drugs are expensive!!
Literally losing over $440,000,000 million a year with only 3.4 mil revenue... Covid is a semi thing of the past now. This has potential to do a reverse split again imho in a year or 2. Not bashing but financials can't add up like this. Hi I'm spending half a Billion dollars a year and have basically zero revenue. Where's this going to come from to keep it going?
Volume is not sustainable imo and did a 15 to 1 Reverse split. They don't even have enough cash to cover 1 quarter. Was $0.86
Mid tripple digit negative profitability over 600% NEGATIVE. I don't think I have ever seen such big negative numbers on any ticker my entire life. While burning over $110,000,000 million a quarter... with revenues of 3 mil..
Profitability
Profit Margin -279.34%
Operating Margin (ttm) -633.66%
Management Effectiveness
Return on Assets (ttm) -35.62%
Return on Equity (ttm) -40.51%
Income Statement
Revenue (ttm) 12.14M
Revenue Per Share (ttm) 0.36
EBITDA -76.66M
Net Income Avi to Common (ttm) -33.92M
Diluted EPS (ttm) -1.00
Cash Flow Statement
Operating Cash Flow (ttm) -71.34M
Levered Free Cash Flow (ttm) -41.5M
massive bio play taking off in pre!
jhpratt@alphavestcapital.com is my email.Please email me insights into eigr.
alphavestcapital.com
MOST IMPORTANT SUMMARY SENTENCES IN THE LANCET ARTICLE:(paraphrased: EIGR’s interferon works better than monoclonal antibodies at reducing covid viral load.Plus, EIGR’s interferon can be administered on an outpatient basis. )"Added value of this study This study shows that a single subcutaneous injection of 180 µg peginterferon lambda has an antiviral effect in outpatients with COVID-19. The decline in viral load was greater with peginterferon lambda treatment than with placebo. The more rapid viral load decline and higher clearance rate were most pronounced in those with high viral loads, a finding also reported with monoclonal antibody therapies in patients with COVID-19. However, the magnitude of the viral load decline compared with that of placebo was much greater with peginterferon lambda than has been reported with monoclonal antibody therapies to date. Peginterferon lambda was safe and well tolerated in outpatients with mild-to-moderate COVID-19, with a similar side-effect profile to that of placebo and no concerning laboratory adverse events. Implications of all the available evidence No approved therapy exists for outpatients with COVID-19. This study showed that peginterferon lambda accelerated viral clearance, particularly in those with high baseline viral loads, highlighting the importance of quantitative viral load testing in the assessment of antiviral agents for patients with COVID-19. Treatment early in the course of disease might prevent clinical deterioration and shorten the duration of viral shedding, which might have an important public health effect by reducing transmission and reducing the duration of self-isolation."
Let’s go over $20...
They say the right things in the conference call it should go bananas. The drug does have covid implications https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19
You think this rocks tomorrow penny chatter?
Think someone will be stated it. I looked and couldn't find it
Who’s the buyer?
I couldn’t find it...
Folks miss the covid implications here and they already have a buyer here https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19
It will sink it the magnitude of this drug, extending the life of these
children 2-1/2 years ....
I agree as it has 80% institutional ownership
Over $20 on Monday......
They didn't have to halt for this lol
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies
https://medlineplus.gov/genetics/condition/hutchinson-gilford-progeria-syndrome/
Progeria
Also known as: hutchinson-gilford progeria syndrome
OVERVIEW
SYMPTOMS
DIAGNOSIS
TREATMENT
A progressive genetic disorder where symptoms of aging are manifested at an early age.
How common is condition?
Extremely rare (Fewer than 1,000 cases per year in US)
Is condition treatable?
Treatments can help manage condition, no known cure
Does diagnosis require lab test or imaging?
Requires lab test or imaging
Condition Highlight
Present at birth, onset can be infantile or juvenile
Condition Highlight
May be dangerous or life threatening
Condition Highlight
Family history may increase likelihood
What kind of fda approval don't see interest?
HALTED PENDING NEWS 11/20/2020 16:53:30 EIGR Eiger BioPharma NASDAQ
T1
EIGR - Lambda is most paradoxical interferon :
“ IFN-lambda responses to dsRNA in the human infant airway epithelium are regulated by p38-MAPK and NF-kB signaling. High in vivo IFN-lambda production is influenced by virus type and associated with recurrent respiratory sick visits in young children.”
https://scholar.google.com.hk/scholar?start=50&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DpIKe3q7igMIJ
A mutual friend we have really likes it.
Small share structure is compelling...
EIGR is expected to release interim data from its Stanford Lambda Trial - I’m not too excited, given the emergent need for any slightly positive data regarding the treatment of SARS2 -see Remdesivir 4 day advantage- and the failure of the data monitoring committee - who already had their interim look/- to halt the study on efficacy - a little bird told me (when I was a vocal advocate of EIGR on Twitter)- that the data was less than compelling to that point weeks ago - certainly that might have changed. The recent insider buy certainly makes on hopeful that it has. A recent seeking alpha pump suggests the upcoming Progeria approval carries tge rest of the pipeline - have you seen how rare Progeria is?
EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.”
https://www.frontiersin.org/articles/10.3389/fneur.2020.00146/full
On EIGR (Lambda is IFN III) “Treatment with type I and III IFNs can dramatically inhibit SARS-CoV-2 replication in primary human airway epithelial cells with the corresponding induction of ISGs.22 The role of type III IFNs in the suppression of virus replication has been highlighted.23,24 Type III IFN shows a better treatment option than type I IFN for influenza A virus-induced disease for its induction of antiviral immunity without the pro-inflammatory responses.”
https://www.biorxiv.org/content/10.1101/2020.07.26.222026v1.full.pdf
EIGR “IFN-Lambda4 showed a strong therapeutic effect in reducing MERS-CoV infection with higher induction of IFN-stimulated genes. Thus, IFN-? has a decisive function in the respiratory epithelium that greatly limits MERS-CoV replication, and may be a key cytokine for better therapeutic outcomes against MERS-CoV infection in respiratory tract.” Success w/1 coronavirus is Promising-awaiting word from Stanford on interim dat in SARS-2 by summer’s end.
https://scholar.google.com/scholar?start=10&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DG9p7gPGYVVwJ
EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.” https://www.google.com/amp/s/www.the-scientist.com/news-opinion/seeking-an-early-covid-19-drug-researchers-look-to-interferons-67753/amp
New EIGR LAMBDA Trial in Canada -Why would Ontario be starting a new Lambda Trial without positive interim data in this SINGLE BLINDED trial - so Stanford researchers know that this 28 day follow up Trial is working and are sharing this fact with their colleagues in Canada. Dr Feld - Principal Investigator in Canada trained at the NIH and Hopkins.
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Open-label, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Jordan Feld, Principal Investigator
University Health Network
Researchers will evaluate the drug peginterferon-lambda (PegIFN-) in ambulatory and hospitalized patients with mild to moderate COVID-19. Peginterferon-lambda has already been used to treat other viral diseases, such as hepatitis B and C. This research will shed light on whether it improves the ability of individuals to clear the virus that causes COVID-19.
https://news.ontario.ca/opo/en/2020/07/ontario-announces-next-round-of-research-projects-to-fight-covid-19.html
EIGR Antiviral Anti ARDS Mechanism of Action -Derek Lowe : “Compared to influenza A virus infection in the same ferret model, the coronavirus transcriptional response was much less dramatic, but very distinctive. The team was even able to check transcription in human lung tissue (2 post-mortem samples compared to 2 different healthy patients). That’s a very small sample, necessarily, but it showed a very similar profile: no interferon upregulation and plenty of cytokine transcription. They were able to check circulating levels of these in a larger number of patients (24 infected cases versus 24 uninfected controls), and these results were also consistent: they tested negative for interferon, but showed elevation of CXCL9 (which attracts T cells) and CXCL16 (which attracts NK cells), CCL8 and CCL2 (recruiting monocytes and/or macrophages), and CXCL8 (which attracts neutrophils). A sudden oversupply of these cell types might be behind the pathology of the disease, which could be characterized, if these hypotheses are correct, as a uniquely imbalanced response: far too little interferon and far too many cytokines, too early.
I expect we’ll see quite a few other papers in this area; we’ll see if this picture holds up. But it certainly seems consistent with what people have been seeing in the clinic, and it bodes well for the therapies that are aiming to dampen the cytokine response pathways. Does this mean that administration of IFN-I or IFN-III would also be beneficial?”
https://blogs.sciencemag.org/pipeline/archives/2020/05/21/there-may-be-a-unique-coronavirus-immune-response
EIGR for COVID ARDS -“We conclude that IFN ? constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID -19 such as pneumonia and acute respiratory distress syndrome (ARDS )”
https://www.embopress.org/doi/full/10.15252/emmm.202012465P
EIGR Positive Data from Stanford Soon “IFN-? has a decisive function in the respiratory epithelium that greatly limits MERS-CoV replication, and may be a key cytokine for better therapeutic outcomes against MERS-CoV infection in respiratory tract.” https://scholar.google.com/scholar?start=10&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DG9p7gPGYVVwJ
EIGR on watch...
https://t.co/c45A6ijrOt?amp=1
8.4M common shares outstanding
$49M cash and investments as of March 31, 2017
• Resources expected to fund operations through mid-2018
Oppenheimer Reaffirms $34 Target On Eiger Biopharmaceuticals (EIGR), Reaffirms “Buy” Rating
https://www.whatsonthorold.com/2017/07/31/oppenheimer-reaffirms-34-0000-target-on-eiger-biopharmaceuticals-eigr-reaffirms-buy-rating-profile-of-1-analysts-covering-pbf-logistics-lp-pbfx/
Out at $9.60. But way stronger than had anticipated as it has continued to go up to the HOD.
Much potential and hope to get back in if/when it begin to fill the gap. It seems that this is so thinly traded that it will revisit the gap.
EIGR
Followers
|
32
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1047
|
Created
|
12/03/14
|
Type
|
Free
|
Moderators |
About the Proposed Merger
Existing Eiger stockholders as well as investors in the contemporaneous financing will receive newly issued shares of Celladon common stock in connection with the proposed merger. Celladon is expected to issue approximately 85.0 million new shares of its common stock to Eiger stockholders and participants in the financing. On a pro forma basis for the combined company, current Celladon shareholders are expected to own approximately 22%, current Eiger shareholders approximately 45% and the new Eiger investor syndicate approximately 33%, each on a fully-diluted basis.
The transaction has been unanimously approved by the boards of directors of both companies, and a majority of Eiger stockholders have agreed to vote in favor of the transaction. The proposed merger is expected to close in the first half of 2016, subject to the approval of the stockholders of each company as well as regulatory approval and other customary conditions. The merger agreement contains further details with respect to the proposed merger.
Celladon’s exclusive financial advisor in the transaction is Wedbush PacGrow Healthcare. Jefferies LLC is acting as lead financial advisor to Eiger and Piper Jaffray is acting as financial advisor. Pillsbury Winthrop Shaw Pittman LLP served as legal counsel to Celladon and Cooley LLP served as legal counsel to Eiger.
Chart
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |